Apply to Join the Cancer Immunotherapy Guidelines Oversight Committee

By SITC Scientific Publications News posted 02-26-2025 14:58

  

The Society for Immunotherapy of Cancer (SITC) is seeking volunteers to join the Cancer Immunotherapy Guidelines (CIG) Oversight Committee, which plays a key role in guiding the society’s clinical practice guideline development and dissemination strategy.

The CIG Oversight Committee oversees the development and updating of new and existing cancer immunotherapy clinical practice guidelines (CPGs) by setting the policies and protocols for SITC guidelines as well as the standards the Expert Panels must meet to ensure the recommendations are unbiased, relevant, and facilitate clinical decision-making leading to optimal patient care. The committee also provides strategic insights into relevant and optimal dissemination and uptake efforts. 

The position has a three-year term with an annual time commitment of approximately 3–5 hours, consisting of virtual meetings and email communication.

Ideal Candidate Profile:

  • Clinicians from both academic and community settings as well as nurses, patient/patient advocates, physician assistants, healthcare administrators and other individuals with experience in the field of cancer immunotherapy are encouraged to apply. Experience in developing or advising on clinical practice guidelines (CPG) with SITC or another relevant organization preferred.  Those without relevant CPG experience must be a SITC member to apply.
  • For clinical applicants, at least six years of experience in the field of cancer immunotherapy required. Other applicants must have demonstrated interest in cancer immunotherapy and/or dedication to optimizing cancer patient outcomes.  
  • Please note: Due to applicable guideline development conflict of interest standards, individuals currently employed by an industry or biotech organization are not eligible to serve on the CIG Oversight Committee.

Apply by Monday, March 31 for a chance to help shape the future of SITC’s Cancer Immunotherapy Guidelines program!

0 comments
4 views

Permalink